Role of the Skin Biopsy in the Diagnosis of Atypical Hemolytic Uremic Syndrome
- 1 May 2015
- journal article
- research article
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 37 (5) , 349-359
Abstract
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a prototypic thrombotic microangiopathy attributable to complement dysregulation. In the absence of complement inhibition, progressive clinical deterioration occurs. The authors postulated that a biopsy of normal skin could corroborate the diagnosis of aHUS through the demonstration of vascular deposits of C5b-9. Materials and Methods: Biopsies of normal skin from 22 patients with and without aHUS were processed for routine light microscopy and immunofluorescent studies. An assessment was made for vascular C5b-9 deposition immunohistochemically and by immunofluorescence. The biopsies were obtained primarily from the forearm and/or deltoid. Results: Patients with classic features of aHUS showed insidious microvascular changes including loose luminal platelet thrombi, except in 2 patients in whom a striking thrombogenic vasculopathy was apparent in biopsied digital ulcers. Extensive microvascular deposits of the membrane attack complex/C5b-9 were identified, excluding 1 patient in whom eculizumab was initiated before biopsy. In 5 of the 7 patients where follow-up was available, the patients exhibited an excellent treatment response to eculizumab. Patients without diagnostic clinical features of aHUS failed to show significant vascular deposits of complement, except 2 patients with thrombotic thrombocytopenic purpura including 1 in whom a Factor H mutation was identified. Conclusions: In a clinical setting where aHUS is an important diagnostic consideration, extensive microvascular deposition of C5b-9 supports the diagnosis of either aHUS or a subset of thrombotic thrombocytopenic purpura patients with concomitant complement dysregulation; significant vascular C5b-9 deposition predicts clinical responsiveness to eculizumab.Keywords
This publication has 27 references indexed in Scilit:
- Partial ADAMTS13 deficiency in atypical hemolytic uremic syndromeBlood, 2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal TransplantationAmerican Journal of Transplantation, 2012
- Complement activation in thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2012
- Structural basis for engagement by complement factor H of C3b on a self surfaceNature Structural & Molecular Biology, 2011
- Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulationJournal of Clinical Investigation, 2010
- Safety and Long-Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic–Uremic SyndromeAmerican Journal of Transplantation, 2009
- The Complement Factor H R1210C Mutation Is Associated With Atypical Hemolytic Uremic SyndromeJournal of the American Society of Nephrology, 2008
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008
- Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuriaNature Biotechnology, 2007